Cargando…

Patient respiratory‐triggered quantitative T(2) mapping in the pancreas

BACKGROUND: Long acquisition times and motion sensitivity limit T(2) mapping in the abdomen. Accelerated mapping at 3 T may allow for quantitative assessment of diffuse pancreatic disease in patients during free‐breathing. PURPOSE: To test the feasibility of respiratory‐triggered quantitative T(2) a...

Descripción completa

Detalles Bibliográficos
Autores principales: Vietti Violi, Naïk, Hilbert, Tom, Bastiaansen, Jessica A.M., Knebel, Jean‐Francois, Ledoux, Jean‐Baptiste, Stemmer, Alto, Meuli, Reto, Kober, Tobias, Schmidt, Sabine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6766866/
https://www.ncbi.nlm.nih.gov/pubmed/30637852
http://dx.doi.org/10.1002/jmri.26612
_version_ 1783454785947566080
author Vietti Violi, Naïk
Hilbert, Tom
Bastiaansen, Jessica A.M.
Knebel, Jean‐Francois
Ledoux, Jean‐Baptiste
Stemmer, Alto
Meuli, Reto
Kober, Tobias
Schmidt, Sabine
author_facet Vietti Violi, Naïk
Hilbert, Tom
Bastiaansen, Jessica A.M.
Knebel, Jean‐Francois
Ledoux, Jean‐Baptiste
Stemmer, Alto
Meuli, Reto
Kober, Tobias
Schmidt, Sabine
author_sort Vietti Violi, Naïk
collection PubMed
description BACKGROUND: Long acquisition times and motion sensitivity limit T(2) mapping in the abdomen. Accelerated mapping at 3 T may allow for quantitative assessment of diffuse pancreatic disease in patients during free‐breathing. PURPOSE: To test the feasibility of respiratory‐triggered quantitative T(2) analysis in the pancreas and correlate T(2)‐values with age, body mass index, pancreatic location, main pancreatic duct dilatation, and underlying pathology. STUDY TYPE: Retrospective single‐center pilot study. POPULATION: Eighty‐eight adults. FIELD STRENGTH/SEQUENCE: Ten‐fold accelerated multiecho‐spin‐echo 3 T MRI sequence to quantify T(2) at 3 T. ASSESSMENT: Two radiologists independently delineated three regions of interest inside the pancreatic head, body, and tail for each acquisition. Means and standard deviations for T(2) values in these regions were determined. T(2)‐value variation with demographic data, intraparenchymal location, pancreatic duct dilation, and underlying pancreatic disease was assessed. STATISTICAL TESTS: Interreader reliability was determined by calculating the interclass coefficient (ICCs). T(2) values were compared for different pancreatic locations by analysis of variance (ANOVA). Interpatient associations between T(2) values and demographical, clinical, and radiological data were calculated (ANOVA). RESULTS: The accelerated T(2) mapping sequence was successfully performed in all participants (mean acquisition time, 2:48 ± 0:43 min). Low T(2) value variability was observed across all patients (intersubject) (head: 60.2 ± 8.3 msec, body: 63.9 ± 11.5 msec, tail: 66.8 ± 16.4 msec). Interreader agreement was good (ICC, 0.82, 95% confidence interval: 0.77–0.86). T(2)‐values differed significantly depending on age (P < 0.001), location (P < 0.001), main pancreatic duct dilatation (P < 0.001), and diffuse pancreatic disease (P < 0.03). DATA CONCLUSION: The feasibility of accelerated T(2) mapping at 3 T in moving abdominal organs was demonstrated in the pancreas, since T(2) values were stable and reproducible. In the pancreatic parenchyma, T(2)‐values were significantly dependent on demographic and clinical parameters. Level of Evidence: 4 Technical Efficacy: Stage 1 J. Magn. Reson. Imaging 2019;50:410–416.
format Online
Article
Text
id pubmed-6766866
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-67668662019-10-01 Patient respiratory‐triggered quantitative T(2) mapping in the pancreas Vietti Violi, Naïk Hilbert, Tom Bastiaansen, Jessica A.M. Knebel, Jean‐Francois Ledoux, Jean‐Baptiste Stemmer, Alto Meuli, Reto Kober, Tobias Schmidt, Sabine J Magn Reson Imaging Original Research BACKGROUND: Long acquisition times and motion sensitivity limit T(2) mapping in the abdomen. Accelerated mapping at 3 T may allow for quantitative assessment of diffuse pancreatic disease in patients during free‐breathing. PURPOSE: To test the feasibility of respiratory‐triggered quantitative T(2) analysis in the pancreas and correlate T(2)‐values with age, body mass index, pancreatic location, main pancreatic duct dilatation, and underlying pathology. STUDY TYPE: Retrospective single‐center pilot study. POPULATION: Eighty‐eight adults. FIELD STRENGTH/SEQUENCE: Ten‐fold accelerated multiecho‐spin‐echo 3 T MRI sequence to quantify T(2) at 3 T. ASSESSMENT: Two radiologists independently delineated three regions of interest inside the pancreatic head, body, and tail for each acquisition. Means and standard deviations for T(2) values in these regions were determined. T(2)‐value variation with demographic data, intraparenchymal location, pancreatic duct dilation, and underlying pancreatic disease was assessed. STATISTICAL TESTS: Interreader reliability was determined by calculating the interclass coefficient (ICCs). T(2) values were compared for different pancreatic locations by analysis of variance (ANOVA). Interpatient associations between T(2) values and demographical, clinical, and radiological data were calculated (ANOVA). RESULTS: The accelerated T(2) mapping sequence was successfully performed in all participants (mean acquisition time, 2:48 ± 0:43 min). Low T(2) value variability was observed across all patients (intersubject) (head: 60.2 ± 8.3 msec, body: 63.9 ± 11.5 msec, tail: 66.8 ± 16.4 msec). Interreader agreement was good (ICC, 0.82, 95% confidence interval: 0.77–0.86). T(2)‐values differed significantly depending on age (P < 0.001), location (P < 0.001), main pancreatic duct dilatation (P < 0.001), and diffuse pancreatic disease (P < 0.03). DATA CONCLUSION: The feasibility of accelerated T(2) mapping at 3 T in moving abdominal organs was demonstrated in the pancreas, since T(2) values were stable and reproducible. In the pancreatic parenchyma, T(2)‐values were significantly dependent on demographic and clinical parameters. Level of Evidence: 4 Technical Efficacy: Stage 1 J. Magn. Reson. Imaging 2019;50:410–416. John Wiley and Sons Inc. 2019-01-13 2019-08 /pmc/articles/PMC6766866/ /pubmed/30637852 http://dx.doi.org/10.1002/jmri.26612 Text en © 2019 The Authors. Journal of Magnetic Resonance Imaging published by Wiley Periodicals, Inc. on behalf of International Society for Magnetic Resonance in Medicine. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research
Vietti Violi, Naïk
Hilbert, Tom
Bastiaansen, Jessica A.M.
Knebel, Jean‐Francois
Ledoux, Jean‐Baptiste
Stemmer, Alto
Meuli, Reto
Kober, Tobias
Schmidt, Sabine
Patient respiratory‐triggered quantitative T(2) mapping in the pancreas
title Patient respiratory‐triggered quantitative T(2) mapping in the pancreas
title_full Patient respiratory‐triggered quantitative T(2) mapping in the pancreas
title_fullStr Patient respiratory‐triggered quantitative T(2) mapping in the pancreas
title_full_unstemmed Patient respiratory‐triggered quantitative T(2) mapping in the pancreas
title_short Patient respiratory‐triggered quantitative T(2) mapping in the pancreas
title_sort patient respiratory‐triggered quantitative t(2) mapping in the pancreas
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6766866/
https://www.ncbi.nlm.nih.gov/pubmed/30637852
http://dx.doi.org/10.1002/jmri.26612
work_keys_str_mv AT viettiviolinaik patientrespiratorytriggeredquantitativet2mappinginthepancreas
AT hilberttom patientrespiratorytriggeredquantitativet2mappinginthepancreas
AT bastiaansenjessicaam patientrespiratorytriggeredquantitativet2mappinginthepancreas
AT knebeljeanfrancois patientrespiratorytriggeredquantitativet2mappinginthepancreas
AT ledouxjeanbaptiste patientrespiratorytriggeredquantitativet2mappinginthepancreas
AT stemmeralto patientrespiratorytriggeredquantitativet2mappinginthepancreas
AT meulireto patientrespiratorytriggeredquantitativet2mappinginthepancreas
AT kobertobias patientrespiratorytriggeredquantitativet2mappinginthepancreas
AT schmidtsabine patientrespiratorytriggeredquantitativet2mappinginthepancreas